Possible offerHealthcare16 November 2026

Wolfram Resources Plc to acquire Ellipses Pharma Limited

Verified deal facts, source-backed narrative, and the Exit Mode founder lens for SME readers preparing to sell.

Deal facts

Buyer
Wolfram Resources Plc
Target
Ellipses Pharma Limited
Deal value
Not disclosed
Announced
16 November 2026
Status
Possible offer
Sector
Healthcare
Country
United Kingdom
Consideration
shares
What we know

Wolfram Resources Plc (LSE: WFR), a Main Market listed special purpose acquisition company, confirmed on 16 November 2026 that it was in active discussions about a potential acquisition of Ellipses Pharma Ltd. The statement responded to press speculation. Because the deal would be an initial transaction under UKLR 13.4.2R, Wolfram asked the FCA to suspend the listing of its ordinary shares from 7.30 a.m. that day, and trading on the Main Market was suspended as well.

On 18 November 2026 Wolfram announced that it had signed a non-binding Memorandum of Understanding with Ellipses covering the proposed acquisition of Ellipses' entire issued share capital. The enlarged group would be re-listed on the Main Market in the Equity Shares (Commercial Companies) category. Consideration is expected to be satisfied in new Wolfram ordinary shares, with final terms to be agreed after due diligence, and a fundraise is expected alongside the relisting.

Ellipses is a London-headquartered drug development company focused exclusively on cancer, founded in 2017 by Professor Sir Chris Evans OBE. Its portfolio includes EP0031 (lunbotinib), a selective RET inhibitor in Phase 2 for RET-altered non-small cell lung cancer and partnered with Kelun-Biotech, and EP0062 (vosilasarm), an oral selective androgen receptor modulator in Phase 2 for ER+/HER2- breast cancer. Its Scientific Advisory Group includes more than 300 oncology experts. Wolfram has appointed Berenberg as Sponsor and Financial Adviser, and AlbR Capital Limited is its corporate broker.

Technical, financial and legal due diligence began immediately, with completion of the acquisition, fundraise and relisting targeted for early 2027. The transaction will be conditional on, among other things, satisfactory technical, financial and legal due diligence, agreement of final terms and definitive documentation, FCA approval and publication of a prospectus, shareholder approval, Takeover Panel approval of a Rule 9 waiver, and admission of the enlarged share capital to the Official List and the Main Market. Wolfram expects its shares to remain suspended until completion, when the existing listing is expected to be cancelled ahead of re-admission, or until an announcement that the deal will not proceed. Because the commercial terms have not yet been agreed, Wolfram says there can be no certainty that the transaction will proceed, nor on what terms.

Deal timeline

2 updates
  1. Possible offer

    Proposed Acquisition of Ellipses Pharma Limited

    Disclaimer* WOLFRAM RESOURCES PLC ("Wolfram" or the "Company") Proposed Acquisition of Ellipses Pharma Limited 18 November 2026 Further to the announcement on 16 November 2026, Wolfram Resources Plc (LSE: WFR), the Main Market listed special purpose acquisition company whose ordinary shares are traded on the Equity Shares (Shell Companies) listing category, is pleased to announce th

    LSE RNS
  2. Speculation response

    Wolfram Resources confirms active discussions on potential acquisition of Ellipses Pharma; listing and trading suspended

    The Company confirms that it is in an active discussion regarding the potential acquisition of Ellipses Pharma Ltd

    LSE RNS

For business owners

What would selling your own business involve?

Use the deal as a starting point, not a valuation benchmark. Learn the decisions behind a sale and apply them to your own preparation.

Guides are free to read. Free tools require email access; indicative results are not professional advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

Similar deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

Buyer history

Wolfram Resources Plc

See every published Exit Mode archive entry where this buyer appears.

View buyer profile

Methodology

How this page is built

Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.

Back to the archive